Fate Therapeutics, Inc.

Healthcare

NASDAQ:FATE · NASDAQ Global Market

Market Cap $240.11M Beta 2.52 P/E (TTM) -1.9

$2.06 +4.57%

+$0.09 today

52W Low $0.91High $2.88

Vol 4.70M · Avg 2.82M

EPS (TTM)-$1.08

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+62.20%

Period High

$2.84

Period Low

$0.92

Latest

$2.06

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Prelude Therapeutics Incorporated

NASDAQ:PRLD

$352.45M

Nkarta, Inc.

NASDAQ:NKTX

$204.62M

Alector, Inc.

NASDAQ:ALEC

$169.87M

Molecular Partners AG

NASDAQ:MOLN

$154.17M

Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

$143.56M

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

$102.67M

PepGen Inc.

NASDAQ:PEPG

$101.68M

Vor Biopharma Inc.

NASDAQ:VOR

$98.42M

Cassava Sciences, Inc.

SAVA

$63.77M

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

$58.95M

What is the latest FATE filing?

The latest filing shown is 8-K dated Jun 4, 2026.

How many recent filings does FATE have?

Intrinsic Alpha currently shows 20 recent filings for FATE.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.